Ratings Yidu Tech Inc.

Equities

2158

KYG9845C1069

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-05-14 am EDT			5-day change	1st Jan Change
4.26 ^HKD	-0.93%		+0.24%	-15.81%

Apr. 12	Yidu Tech Inc. commences an Equity Buyback Plan for 105,285,814 shares, representing 10% of its issued share capital, under the authorization approved on September 28, 2023.	CI
Jan. 23	Yidu Tech Affiliate Wins Bid for Information Platform for Chaozhou City Medical Group	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
Thanks to a sound financial situation, the firm has significant leeway for investment.
With regards to fundamentals, the enterprise value to sales ratio is at 1.23 for the current period. Therefore, the company is undervalued.
The company appears to be poorly valued given its net asset value.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
YIDU TECH INC.	-15.81%	585M		-
VEEVA SYSTEMS INC.	+5.89%	32.95B		C
PRO MEDICUS LIMITED	+18.09%	7.82B		C-
SECTRA AB	+32.70%	4.17B		B-
EVOLENT HEALTH, INC.	-28.10%	2.72B		C-
OMNICELL, INC.	-18.15%	1.41B		B
LUNIT INC.	-33.33%	1.15B		-
SIMULATIONS PLUS, INC.	+9.61%	980M		C
B-SOFT CO.,LTD.	-37.56%	873M		-
VERADIGM INC.	-26.41%	831M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes